Related Experiment Video
Updated: Jul 29, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects
M M Lakkis1, J A Golden, K S O'Shea
1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, 19104, USA.
Abstract:
Neural tube defects are common and serious human congenital anomalies. These malformations have a multifactorial etiology and can be reproduced in mouse models by mutations of numerous individual genes and by perturbation of multiple environmental factors. The identification of specific genetic interactions affecting neural tube closure will facilitate our understanding of molecular pathways regulating normal neural development and will enhance our ability to predict and modify the incidence of spina bifida and other neural tube defects. Here, we report a genetic interaction between Nf1, encoding the intracellular signal transduction protein neurofibromin, and Pax3, a transcription factor gene mutated in the Splotch mouse. Both Pax3 and Nf1 are important for the development of neural crest-derived structures and the central nervous system. Splotch is an established model of folate-sensitive neural tube defects, and homozygous mutant embryos develop spina bifida and sometimes exencephaly. Neural development is grossly normal in heterozygotes and neural tube defects are not seen. In contrast, we found a low incidence of neural tube defects in heterozygous Splotch mice that also harbored a mutation in one Nf1 allele. All compound homozygotes had severe neural tube defects and died earlier in embryogenesis than either Nf1(-/-) or Sp(-/-) embryos. We also report occasional exencephaly in Nf1(-/-) mice and identify more subtle CNS abnormalities in normal-appearing Nf1(-/-) embryos. Though other genetic loci and environmental factors affect the incidence of neural tube defects in Splotch mice, these results establish Nf1 as the first known gene to act as a modifier of neural tube defects in Splotch.
Insights
Genetic interactions involving neurofibromin (Nf1) and Pax3 modify neural tube defects. This study identifies Nf1 as a modifier gene for spina bifida in mouse models, impacting neural development.
Area of Science:
- Developmental Biology
- Genetics
- Neuroscience
Background:
- Neural tube defects (NTDs) are common congenital anomalies with multifactorial causes.
- Mouse models are crucial for understanding genetic and environmental factors influencing NTDs.
- Pax3 mutations in Splotch mice cause NTDs, serving as a model for folate-sensitive defects.
Purpose of the Study:
- To investigate genetic interactions affecting neural tube closure.
- To identify novel genes that modify the incidence of NTDs.
- To elucidate molecular pathways regulating neural development and NTD prevention.
Main Methods:
- Analysis of mouse models with mutations in Nf1 and Pax3 genes.
- Examination of neural tube closure in heterozygous and homozygous mutant embryos.
- Assessment of central nervous system (CNS) development and survival rates.
Main Results:
- A genetic interaction between Nf1 and Pax3 was identified, affecting neural tube closure.
- Heterozygous Splotch mice with an Nf1 mutation exhibited a low incidence of NTDs.
- Compound homozygous mutants (Nf1 and Pax3) displayed severe NTDs and early embryonic lethality.
Conclusions:
- Nf1 acts as a modifier gene for neural tube defects in the Splotch mouse model.
- This interaction highlights the role of Nf1 in neural development and neural crest formation.
- Understanding these genetic interactions is key to predicting and potentially modifying NTD incidence.
More Related Videos
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
05:44Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1
Published on: May 17, 2024